En klinisk relevant svagt reagerende inhibitor blev fundet hos 1 ud af 65 BeneFIX patienter, som tidligere havde modtaget plasmafremstillede præparater.
A clinically relevant, low responding inhibitor was detected in 1 out of 65 BeneFIX patients who had previously received plasma derived products.